1
|
Zhao Z, Zhu J, Zhou L, Sun N, Chang K, Hu X, Hu Y, Ren M, Cheng Y, Xu D, Xin H, Zhang C. Establishment of a hydrodynamic delivery system in ducks. Transgenic Res 2024; 33:35-46. [PMID: 38461212 DOI: 10.1007/s11248-024-00377-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2023] [Accepted: 02/20/2024] [Indexed: 03/11/2024]
Abstract
Chronic hepatitis B virus (HBV) poses a significant global health challenge as it can lead to acute or chronic liver disease and hepatocellular carcinoma (HCC). To establish a safety experimental model, a homolog of HBV-duck HBV (DHBV) is often used for HBV research. Hydrodynamic-based gene delivery (HGD) is an efficient method to introduce exogenous genes into the liver, making it suitable for basic research. In this study, a duck HGD system was first constructed by injecting the reporter plasmid pLIVE-SEAP via the ankle vein. The highest expression of SEAP occurred when ducks were injected with 5 µg/mL plasmid pLIVE-SEAP in 10% bodyweight volume of physiological saline for 6 s. To verify the distribution and expression of exogenous genes in multiple tissues, the relative level of foreign gene DNA and β-galactosidase staining of LacZ were evaluated, which showed the plasmids and their products were located mainly in the liver. Additionally, β-galactosidase staining and fluorescence imaging indicated the delivered exogenous genes could be expressed in a short time. Further, the application of the duck HGD model on DHBV treatment was investigated by transferring representative anti-HBV genes IFNα and IFNγ into DHBV-infected ducks. Delivery of plasmids expressing IFNα and IFNγ inhibited DHBV infection and we established a novel efficient HGD method in ducks, which could be useful for drug screening of new genes, mRNAs and proteins for anti-HBV treatment.
Collapse
Affiliation(s)
- Zhanji Zhao
- Department of Pathology and Institute of Molecular Pathology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People's Republic of China
- School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People's Republic of China
| | - Jiabing Zhu
- School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People's Republic of China
| | - Lijian Zhou
- School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People's Republic of China
| | - Nan Sun
- School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People's Republic of China
| | - Kaile Chang
- School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People's Republic of China
| | - Xiaoyue Hu
- School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People's Republic of China
- Institute of Translational Medicine, Jiangxi Medical College,, Nanchang University, Nanchang, 330031, People's Republic of China
| | - Yuting Hu
- School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People's Republic of China
- Institute of Translational Medicine, Jiangxi Medical College,, Nanchang University, Nanchang, 330031, People's Republic of China
| | - Mingzhi Ren
- School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People's Republic of China
| | - Yan Cheng
- School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People's Republic of China
| | - Derong Xu
- Institute of Translational Medicine, Jiangxi Medical College,, Nanchang University, Nanchang, 330031, People's Republic of China
| | - Hongbo Xin
- Institute of Translational Medicine, Jiangxi Medical College,, Nanchang University, Nanchang, 330031, People's Republic of China
| | - Chunbo Zhang
- Department of Pathology and Institute of Molecular Pathology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People's Republic of China.
- School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People's Republic of China.
- Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, Ministry of Education, Jiangxi Medical College, Nanchang University, Nanchang, 330031, People's Republic of China.
| |
Collapse
|
2
|
Tsounis EP, Mouzaki A, Triantos C. Nucleic acid vaccines: A taboo broken and prospect for a hepatitis B virus cure. World J Gastroenterol 2021; 27:7005-7013. [PMID: 34887624 PMCID: PMC8613654 DOI: 10.3748/wjg.v27.i41.7005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/18/2021] [Revised: 07/07/2021] [Accepted: 10/14/2021] [Indexed: 02/06/2023] Open
Abstract
Although a prophylactic vaccine is available, hepatitis B virus (HBV) remains a major cause of liver-related morbidity and mortality. Current treatment options are improving clinical outcomes in chronic hepatitis B; however, true functional cure is currently the exception rather than the rule. Nucleic acid vaccines are among the emerging immunotherapies that aim to restore weakened immune function in chronically infected hosts. DNA vaccines in particular have shown promising results in vivo by reducing viral replication, breaking immune tolerance in a sustained manner, or even decimating the intranuclear covalently closed circular DNA reservoir, the hallmark of HBV treatment. Although DNA vaccines encoding surface antigens administered by conventional injection elicit HBV-specific T cell responses in humans, initial clinical trials failed to demonstrate additional therapeutic benefit when administered with nucleos(t)ide analogs. In an attempt to improve vaccine immunogenicity, several techniques have been used, including codon/promoter optimization, coadministration of cytokine adjuvants, plasmids engineered to express multiple HBV epitopes, or combinations with other immunomodulators. DNA vaccine delivery by electroporation is among the most efficient strategies to enhance the production of plasmid-derived antigens to stimulate a potent cellular and humoral anti-HBV response. Preliminary results suggest that DNA vaccination via electroporation efficiently invigorates both arms of adaptive immunity and suppresses serum HBV DNA. In contrast, the study of mRNA-based vaccines is limited to a few in vitro experiments in this area. Further studies are needed to clarify the prospects of nucleic acid vaccines for HBV cure.
Collapse
Affiliation(s)
- Efthymios P Tsounis
- Division of Gastroenterology, Department of Internal Medicine, University of Patras, Patras 26504, Greece
| | - Athanasia Mouzaki
- Division of Hematology, Department of Internal Medicine, University of Patras, Patras 26504, Greece
| | - Christos Triantos
- Division of Gastroenterology, Department of Internal Medicine, University of Patras, Patras 26504, Greece
| |
Collapse
|
3
|
Dhama K, Kumar N, Saminathan M, Tiwari R, Karthik K, Kumar MA, Palanivelu M, Shabbir MZ, Malik YS, Singh RK. Duck virus enteritis (duck plague) - a comprehensive update. Vet Q 2017; 37:57-80. [PMID: 28320263 DOI: 10.1080/01652176.2017.1298885] [Citation(s) in RCA: 56] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Duck virus enteritis (DVE), also called duck plague, is one of the major contagious and fatal diseases of ducks, geese and swan. It is caused by duck enteritis virus (DEV)/Anatid herpesvirus-1 of the genus Mardivirus, family Herpesviridae, and subfamily Alpha-herpesvirinae. Of note, DVE has worldwide distribution, wherein migratory waterfowl plays a crucial role in its transmission within and between continents. Furthermore, horizontal and/ or vertical transmission plays a significant role in disease spread through oral-fecal discharges. Either of sexes from varying age groups of ducks is vulnerable to DVE. The disease is characterized by sudden death, vascular damage and subsequent internal hemorrhage, lesions in lymphoid organs, digestive mucosal eruptions, severe diarrhea and degenerative lesions in parenchymatous organs. Huge economic losses are connected with acute nature of the disease, increased morbidity and mortality (5%-100%), condemnations of carcasses, decreased egg production and hatchability. Although clinical manifestations and histopathology can provide preliminary diagnosis, the confirmatory diagnosis involves virus isolation and detection using serological and molecular tests. For prophylaxis, both live-attenuated and killed vaccines are being used in broiler and breeder ducks above 2 weeks of age. Since DEV is capable of becoming latent as well as shed intermittently, recombinant subunit and DNA vaccines either alone or in combination (polyvalent) are being targeted for its benign prevention. This review describes DEV, epidemiology, transmission, the disease (DVE), pathogenesis, and advances in diagnosis, vaccination and antiviral agents/therapies along with appropriate prevention and control strategies.
Collapse
Affiliation(s)
- Kuldeep Dhama
- a Division of Pathology , ICAR - Indian Veterinary Research Institute , Izatnagar , India
| | - Naveen Kumar
- b National Center for Veterinary Type Cultures, ICAR-National Research Center on Equines , Hisar , India
| | - Mani Saminathan
- a Division of Pathology , ICAR - Indian Veterinary Research Institute , Izatnagar , India
| | - Ruchi Tiwari
- c Department of Veterinary Microbiology and Immunology, College of Veterinary Sciences , Deen Dayal Upadhayay Pashu Chikitsa Vigyan Vishwavidyalay Evum Go-Anusandhan Sansthan (DUVASU) , Mathura , India
| | - Kumaragurubaran Karthik
- d Central University Laboratory , Tamil Nadu Veterinary and Animal Sciences University , Chennai , India
| | - M Asok Kumar
- a Division of Pathology , ICAR - Indian Veterinary Research Institute , Izatnagar , India
| | - M Palanivelu
- a Division of Pathology , ICAR - Indian Veterinary Research Institute , Izatnagar , India
| | - Muhammad Zubair Shabbir
- e Quality Operations Laboratory , University of Veterinary and Animal Sciences , Lahore , Pakistan
| | - Yashpal Singh Malik
- f Division of Biological Standardization , ICAR - Indian Veterinary Research Institute , Bareilly , India
| | - Raj Kumar Singh
- g ICAR - Indian Veterinary Research Institute , Izatnagar , India
| |
Collapse
|
4
|
Affiliation(s)
- Lucyna Cova
- INSERM U1052, Centre de Recherche en Cancérologie de Lyon (CRCL), University Lyon 1, Lyon, France
| |
Collapse
|
5
|
Meunier M, Chemaly M, Dory D. DNA vaccination of poultry: The current status in 2015. Vaccine 2015; 34:202-211. [PMID: 26620840 PMCID: PMC7115526 DOI: 10.1016/j.vaccine.2015.11.043] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2015] [Revised: 11/05/2015] [Accepted: 11/12/2015] [Indexed: 01/13/2023]
Abstract
Poultry DNA vaccination studies are regularly being published since 1993. These studies are mainly, but not only, concerned with vaccination against viruses. The different strategies of improving DNA vaccine efficacies are presented. The fate of the vaccine plasmid, immune properties and other applications are described. Despite the compiling preclinical reports, a poultry DNA vaccine is yet unavailable in the market.
DNA vaccination is a promising alternative strategy for developing new human and animal vaccines. The massive efforts made these past 25 years to increase the immunizing potential of this kind of vaccine are still ongoing. A relatively small number of studies concerning poultry have been published. Even though there is a need for new poultry vaccines, five parameters must nevertheless be taken into account for their development: the vaccine has to be very effective, safe, inexpensive, suitable for mass vaccination and able to induce immune responses in the presence of maternal antibodies (when appropriate). DNA vaccination should meet these requirements. This review describes studies in this field performed exclusively on birds (chickens, ducks and turkeys). No evaluations of avian DNA vaccine efficacy performed on mice as preliminary tests have been taken into consideration. The review first describes the state of the art for DNA vaccination in poultry: pathogens targeted, plasmids used and different routes of vaccine administration. Second, it presents strategies designed to improve DNA vaccine efficacy: influence of the route of administration, plasmid dose and age of birds on their first inoculation; increasing plasmid uptake by host cells; addition of immunomodulators; optimization of plasmid backbones and codon usage; association of vaccine antigens and finally, heterologous prime-boost regimens. The final part will indicate additional properties of DNA vaccines in poultry: fate of the plasmids upon inoculation, immunological considerations and the use of DNA vaccines for purposes other than preventing infectious diseases.
Collapse
Affiliation(s)
- Marine Meunier
- French Agency for Food, Environmental and Occupational Health & Safety (ANSES), Ploufragan/Plouzané Laboratory, Viral Genetics and Biosafety Unit, Ploufragan, France; French Agency for Food, Environmental and Occupational Health & Safety (ANSES), Ploufragan/Plouzané Laboratory, Unit of Hygiene and Quality of Poultry and Pork Products, Ploufragan, France
| | - Marianne Chemaly
- French Agency for Food, Environmental and Occupational Health & Safety (ANSES), Ploufragan/Plouzané Laboratory, Unit of Hygiene and Quality of Poultry and Pork Products, Ploufragan, France
| | - Daniel Dory
- French Agency for Food, Environmental and Occupational Health & Safety (ANSES), Ploufragan/Plouzané Laboratory, Viral Genetics and Biosafety Unit, Ploufragan, France.
| |
Collapse
|
6
|
Guo XQ, Wang LQ, Qiao H, Yang XW, Yang MF, Chen HY. Enhancement of the immunogenicity of a porcine circovirus type 2 DNA vaccine by a recombinant plasmid coexpressing capsid protein and porcine interleukin-6 in mice. Microbiol Immunol 2015; 59:174-80. [DOI: 10.1111/1348-0421.12244] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2014] [Revised: 01/13/2015] [Accepted: 01/28/2015] [Indexed: 01/14/2023]
Affiliation(s)
- Xiao-Qing Guo
- College of Animal Science and Veterinary Medicine; Henan Agricultural University; 63 Nongye Road Zhengzhou 450002
| | - Lin-Qing Wang
- Department of Life Science; Zhengzhou Normal University; Zhengzhou 450044 Henan Province China
| | - Han Qiao
- College of Animal Science and Veterinary Medicine; Henan Agricultural University; 63 Nongye Road Zhengzhou 450002
| | - Xing-Wu Yang
- College of Animal Science and Veterinary Medicine; Henan Agricultural University; 63 Nongye Road Zhengzhou 450002
| | - Ming-Fan Yang
- College of Animal Science and Veterinary Medicine; Henan Agricultural University; 63 Nongye Road Zhengzhou 450002
| | - Hong-Ying Chen
- College of Animal Science and Veterinary Medicine; Henan Agricultural University; 63 Nongye Road Zhengzhou 450002
| |
Collapse
|
7
|
Ferreira HL, Pirlot JF, Reynard F, van den Berg T, Bublot M, Lambrecht B. Immune responses and protection against H5N1 highly pathogenic avian influenza virus induced by the Newcastle disease virus H5 vaccine in ducks. Avian Dis 2013; 56:940-8. [PMID: 23402116 DOI: 10.1637/10148-040812-resnote.1] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Ducks play an important role in the epidemiology of avian influenza, and there is a need for new avian influenza vaccines that are suitable for mass vaccination in ducks. The immune responses as well as highly pathogenic avian influenza (HPAI) H5N1 protection induced by a Newcastle disease virus (NDV) vector expressing an H5N1 hemagglutinin (rNDV-H5) were investigated in mule ducks, a hybrid between Muscovy (Cairina moschata domesticus) males and Pekin (Anas platyrhynchos domesticus) females. Immunological tools to measure NDV and H5-specific serum antibody, mucosal, and cell-mediated immune (CMI) responses in ducks have been validated after infection with the vector NDV and an H5N1 low pathogenic avian influenza virus. The effect of maternally-derived antibodies (MDAs) to NDV on the humoral and CMI responses after NDV-H5 vaccination was also investigated. Our results showed the rNDV-H5 vaccine elicits satisfactory humoral and cellular responses in 11-day-old ducks correlating with a complete clinical and virological protection against the H5N1 strain. However, vaccination with rNDV-H5 in the presence of NDV MDA induced lower NDV-specific serum antibody, mucosal, and CMI responses than in ducks with no MDA, while interestingly the H5-specific serum antibody and duodenal IgY response were higher in ducks with NDV MDA. To our knowledge, this is the first report of the use of an NDV vector in ducks and of an HPAI H5N1 challenge in mule ducks, which appeared to be as resistant as Pekin ducks.
Collapse
Affiliation(s)
- Helena Lage Ferreira
- FZEA-USP, Av. Duque de Caxias Norte, 225, Pirassununga, SP, CEP 13635-900, Brazil
| | | | | | | | | | | |
Collapse
|
8
|
Saade F, Buronfosse T, Guerret S, Pradat P, Chevallier M, Zoulim F, Jamard C, Cova L. In vivo infectivity of liver extracts after resolution of hepadnaviral infection following therapy associating DNA vaccine and cytokine genes. J Viral Hepat 2013; 20:e56-65. [PMID: 23490390 DOI: 10.1111/jvh.12023] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/26/2012] [Accepted: 08/24/2012] [Indexed: 12/19/2022]
Abstract
DNA-based vaccination appears of promise for chronic hepatitis B immunotherapy, although there is an urgent need to increase its efficacy. In this preclinical study, we evaluated the therapeutic benefit of cytokine (IL-2, IFN-γ) genes co-delivery with DNA vaccine targeting hepadnaviral proteins in the chronic duck hepatitis B virus (DHBV) infection model. Then, we investigated the persistence of replication-competent virus in the livers of apparently resolved animals. DHBV carriers received four injections of plasmids encoding DHBV envelope and core alone or co-delivered with duck IL-2 (DuIL-2) or duck IFN-γ (DuIFN-γ) plasmids. After long-term (8 months) follow-up, viral covalently closed circular (ccc) DNA was analysed in duck necropsy liver samples. Liver homogenates were also tested for in vivo infectivity in neonatal ducklings. Co-delivery of DuIFN-γ resulted in significantly lower mean viremia starting from week 21. Viral cccDNA was undetectable by conventional methods in the livers of 25% and 57% of animals co-immunized with DuIL-2 and DuIFN-γ, respectively. Interestingly, inoculation of liver homogenates from 7 such apparently resolved animals, exhibiting cccDNA undetectable in Southern blotting and DHBV expression undetectable or restricted to few hepatocytes, revealed that three liver homogenates transmitted high-titre viremia (3-5×10(10) vge/mL) to naïve animals. In conclusion, our results indicate that IFN-γ gene co-delivery considerably enhances immunotherapeutic efficacy of DNA vaccine targeting hepadnaviral proteins. Importantly, we also showed that livers exhibiting only minute amounts of hepadnaviral cccDNA could induce extremely high-titre infection, highlighting the caution that should be taken in occult hepatitis B patients to prevent HBV transmission in liver transplantation context.
Collapse
Affiliation(s)
- F Saade
- Université de Lyon, Lyon, Lyon, France
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Abdul F, Ndeboko B, Buronfosse T, Zoulim F, Kann M, Nielsen PE, Cova L. Potent inhibition of late stages of hepadnavirus replication by a modified cell penetrating peptide. PLoS One 2012; 7:e48721. [PMID: 23173037 PMCID: PMC3500254 DOI: 10.1371/journal.pone.0048721] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2012] [Accepted: 09/28/2012] [Indexed: 12/17/2022] Open
Abstract
Cationic cell-penetrating peptides (CPPs) and their lipid domain-conjugates (CatLip) are agents for the delivery of (uncharged) biologically active molecules into the cell. Using infection and transfection assays we surprisingly discovered that CatLip peptides were able to inhibit replication of Duck Hepatitis B Virus (DHBV), a reference model for human HBV. Amongst twelve CatLip peptides we identified Deca-(Arg)8 having a particularly potent antiviral activity, leading to a drastic inhibition of viral particle secretion without detectable toxicity. Inhibition of virion secretion was correlated with a dose-dependent increase in intracellular viral DNA. Deca-(Arg)8 peptide did neither interfere with DHBV entry, nor with formation of mature nucleocapsids nor with their travelling to the nucleus. Instead, Deca-(Arg)8 caused envelope protein accumulation in large clusters as revealed by confocal laser scanning microscopy indicating severe structural changes of preS/S. Sucrose gradient analysis of supernatants from Deca-(Arg)8-treated cells showed unaffected naked viral nucleocapsids release, which was concomitant with a complete arrest of virion and surface protein-containing subviral particle secretion. This is the first report showing that a CPP is able to drastically block hepadnaviral release from infected cells by altering late stages of viral morphogenesis via interference with enveloped particle formation, without affecting naked nucleocapsid egress, thus giving a view inside the mode of inhibition. Deca-(Arg)8 may be a useful tool for elucidating the hepadnaviral secretory pathway, which is not yet fully understood. Moreover we provide the first evidence that a modified CPP displays a novel antiviral mechanism targeting another step of viral life cycle compared to what has been so far described for other enveloped viruses.
Collapse
Affiliation(s)
- Fabien Abdul
- Université de Lyon 1, Lyon, France
- Institut National de la Santé et de la Recherche Medicale (INSERM) U1052, Centre de Recherche en Cancérologie de Lyon (CRCL), Lyon, France
- CNRS UMR 5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France
| | - Bénédicte Ndeboko
- Université de Lyon 1, Lyon, France
- Institut National de la Santé et de la Recherche Medicale (INSERM) U1052, Centre de Recherche en Cancérologie de Lyon (CRCL), Lyon, France
- CNRS UMR 5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France
| | - Thierry Buronfosse
- Université de Lyon 1, Lyon, France
- Institut National de la Santé et de la Recherche Medicale (INSERM) U1052, Centre de Recherche en Cancérologie de Lyon (CRCL), Lyon, France
- CNRS UMR 5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France
- VetAgro-Sup, Marcy l'Etoile, France
| | - Fabien Zoulim
- Université de Lyon 1, Lyon, France
- Institut National de la Santé et de la Recherche Medicale (INSERM) U1052, Centre de Recherche en Cancérologie de Lyon (CRCL), Lyon, France
- CNRS UMR 5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France
| | - Michael Kann
- Université de Bordeaux, Microbiologie Fondamentale et Pathogénicité, UMR 5234, Bordeaux, France
- CNRS, Microbiologie fondamentale et Pathogénicité, UMR 5234, Bordeaux, France
- CHU de Bordeaux, Bordeaux, France
| | - Peter E. Nielsen
- Department of Cellular and Molecular Medicine and Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, The Panum Institute, University of Copenhagen, Copenhagen N, Denmark
| | - Lucyna Cova
- Université de Lyon 1, Lyon, France
- Institut National de la Santé et de la Recherche Medicale (INSERM) U1052, Centre de Recherche en Cancérologie de Lyon (CRCL), Lyon, France
- CNRS UMR 5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France
- * E-mail:
| |
Collapse
|
10
|
Khawaja G, Buronfosse T, Jamard C, Abdul F, Guerret S, Zoulim F, Luxembourg A, Hannaman D, Evans CF, Hartmann D, Cova L. In vivo electroporation improves therapeutic potency of a DNA vaccine targeting hepadnaviral proteins. Virology 2012; 433:192-202. [PMID: 22921316 DOI: 10.1016/j.virol.2012.07.014] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2012] [Revised: 06/01/2012] [Accepted: 07/16/2012] [Indexed: 12/15/2022]
Abstract
This preclinical study investigated the therapeutic efficacy of electroporation (EP)-based delivery of plasmid DNA (pDNA) encoding viral proteins (envelope, core) and IFN-γ in the duck model of chronic hepatitis B virus (DHBV) infection. Importantly, only DNA EP-therapy resulted in a significant decrease in mean viremia titers and in intrahepatic covalently closed circular DNA (cccDNA) levels in chronic DHBV-carrier animals, compared with standard needle pDNA injection (SI). In addition, DNA EP-therapy stimulated in all virus-carriers a humoral response to DHBV preS protein, recognizing a broader range of major antigenic regions, including neutralizing epitopes, compared with SI. DNA EP-therapy led also to significant higher intrahepatic IFN-γ RNA levels in DHBV-carriers compared to other groups, in the absence of adverse effects. We provide the first evidence on DNA EP-therapy benefit in terms of hepadnaviral infection clearance and break of immune tolerance in virus-carriers, supporting its clinical application for chronic hepatitis B.
Collapse
MESH Headings
- Animals
- Antibodies, Viral/biosynthesis
- Antibodies, Viral/immunology
- Chronic Disease
- DNA, Circular/genetics
- DNA, Circular/immunology
- Disease Models, Animal
- Ducks
- Electroporation
- Epitopes
- Hepadnaviridae Infections/immunology
- Hepadnaviridae Infections/prevention & control
- Hepadnaviridae Infections/veterinary
- Hepadnaviridae Infections/virology
- Hepatitis B Vaccines/administration & dosage
- Hepatitis B Vaccines/immunology
- Hepatitis B Virus, Duck/immunology
- Hepatitis, Viral, Animal/immunology
- Hepatitis, Viral, Animal/prevention & control
- Hepatitis, Viral, Animal/virology
- Immune Tolerance
- Immunity, Humoral
- Interferon-gamma/biosynthesis
- Interferon-gamma/immunology
- Plasmids
- Vaccines, DNA/administration & dosage
- Vaccines, DNA/immunology
- Viral Core Proteins/genetics
- Viral Core Proteins/immunology
- Viral Envelope Proteins/genetics
- Viral Envelope Proteins/immunology
- Viremia/immunology
- Viremia/prevention & control
- Viremia/veterinary
- Viremia/virology
Collapse
|
11
|
Abstract
Despite many years of research, human DNA vaccines have yet to fulfill their early promise. Over the past 15 years, multiple generations of DNA vaccines have been developed and tested in preclinical models for prophylactic and therapeutic applications in the areas of infectious disease and cancer, but have failed in the clinic. Thus, while DNA vaccines have achieved successful licensure for veterinary applications, their poor immunogenicity in humans when compared with traditional protein-based vaccines has hindered their progress. Many strategies have been attempted to improve DNA vaccine potency including use of more efficient promoters and codon optimization, addition of traditional or genetic adjuvants, electroporation, intradermal delivery and various prime-boost strategies. This review summarizes these advances in DNA vaccine technologies and attempts to answer the question of when DNA vaccines might eventually be licensed for human use.
Collapse
Affiliation(s)
- Fadi Saade
- Vaxine Pty Ltd, Bedford Park, Adelaide 5042, Australia
| | - Nikolai Petrovsky
- Vaxine Pty Ltd, Bedford Park, Adelaide 5042, Australia
- Department of Diabetes and Endocrinology, Flinders Medical Centre/Flinders University, Adelaide 5042, Australia
| |
Collapse
|
12
|
Chen HY, Cui P, Cui BA, Li HP, Jiao XQ, Zheng LL, Cheng G, Chao AJ. Immune responses of chickens inoculated with a recombinant fowlpox vaccine coexpressing glycoprotein B of infectious laryngotracheitis virus and chicken IL-18. ACTA ACUST UNITED AC 2011; 63:289-95. [DOI: 10.1111/j.1574-695x.2011.00850.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Hong-Ying Chen
- College of Animal Science and Veterinary Medicine; Henan Agricultural University; Zhengzhou; Henan Province; China
| | - Pei Cui
- Henan Center for Animal Disease Control & Prevention; Animal Husbandry Bureau of Henan Province; Zhengzhou; Henan Province; China
| | - Bao-An Cui
- College of Animal Science and Veterinary Medicine; Henan Agricultural University; Zhengzhou; Henan Province; China
| | - He-Ping Li
- College of Animal Science and Veterinary Medicine; Henan Agricultural University; Zhengzhou; Henan Province; China
| | - Xian-Qin Jiao
- College of Animal Science and Veterinary Medicine; Henan Agricultural University; Zhengzhou; Henan Province; China
| | - Lan-Lan Zheng
- College of Animal Science and Veterinary Medicine; Henan Agricultural University; Zhengzhou; Henan Province; China
| | - Guo Cheng
- Henan Center for Animal Disease Control & Prevention; Animal Husbandry Bureau of Henan Province; Zhengzhou; Henan Province; China
| | - An-Jun Chao
- College of Animal Science and Veterinary Medicine; Henan Agricultural University; Zhengzhou; Henan Province; China
| |
Collapse
|
13
|
Wang XY, Zhang XX, Yao X, Jiang JH, Xie YH, Yuan ZH, Wen YM. Serum HBeAg sero-conversion correlated with decrease of HBsAg and HBV DNA in chronic hepatitis B patients treated with a therapeutic vaccine. Vaccine 2010; 28:8169-74. [PMID: 20937312 DOI: 10.1016/j.vaccine.2010.09.093] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2010] [Revised: 09/20/2010] [Accepted: 09/24/2010] [Indexed: 01/27/2023]
Abstract
Currently, there are various approaches for developing therapeutic vaccines for chronic hepatitis B patients. Previously, an antigen-antibody-based therapeutic vaccine (YIC) has been conducted in a double-blind placebo controlled phase IIb clinical trial in 242 chronic hepatitis B patients. At the end of follow-up for 24 weeks, HBeAg sero-conversion rate was 21.6% in the 60 μg immunized group, compared to 9% in the alum immunized control group (p=0.03). To analyze the correlation between HBeAg-seroconversion, and decrease of serum HBsAg and HBV DNA, serum samples were back quantified for serum HBsAg and HBV DNA collected at baseline, end of treatment, and end of follow-up from patients who were treated either with 60 μg of YIC, or with placebo. Patients were dichotomized to HBeAg sero-converted and non-converted groups in comparison with patients in the placebo group. The correlations between HBeAg seroconversion and the decrease of HBsAg, HBV DNA and ALT levels during study period were analyzed using a logistic regression model. Results showed marked and sustained reduction of HBsAg, HBV DNA and ALT level in HBeAg sero-converted patients compared to those in patients of HBeAg non-converted and placebo groups. Reduction of HBV DNA and elevation of ALT was markedly associated with HBeAg seroconversion with an adjusted OR of 0.09 (95%CI: 0.01-0.62) and 0.08 (95%CI: 0.02-0.37) respectively after adjusted by age and sex, while reduction of HBsAg level was close to of significance (p=0.054). Analysis indicated that HBeAg sero-conversion was a reasonable endpoint for therapeutic vaccination.
Collapse
Affiliation(s)
- Xuan-Yi Wang
- Institutes of Biomedical Sciences, Fudan University, Shanghai, People's Republic of China
| | | | | | | | | | | | | |
Collapse
|
14
|
Feng F, Teoh CQ, Qiao Q, Boyle D, Jilbert AR. The development of persistent duck hepatitis B virus infection can be prevented using antiviral therapy combined with DNA or recombinant fowlpoxvirus vaccines. Vaccine 2010; 28:7436-43. [PMID: 20833122 DOI: 10.1016/j.vaccine.2010.08.091] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2010] [Revised: 08/12/2010] [Accepted: 08/24/2010] [Indexed: 10/19/2022]
Abstract
We recently reported the development of a successful post-exposure combination antiviral and "prime-boost" vaccination strategy using the duck hepatitis B virus (DHBV) model of human hepatitis B virus infection. The current study aimed to simplify the vaccination strategy and to test the post-exposure efficacy of combination therapy with the Bristol-Myers Squibb antiviral drug, entecavir (ETV) and either a single dose of DHBV DNA vaccines on day 0 post-infection (p.i.) or a single dose of recombinant fowlpoxvirus (rFPV-DHBV) vaccines on day 7 p.i. Whilst untreated control ducks infected with an equal dose of DHBV all developed persistent and wide spread DHBV infection of the liver, ducks treated with ETV combined with either the DHBV DNA vaccines on day 0 p.i. or the rFPV-DHBV vaccines on day 7 p.i. had no detectable DHBV-infected hepatocytes by day 14 p.i. and were protected from the development of persistent DHBV infection.
Collapse
Affiliation(s)
- Feng Feng
- School of Molecular and Biomedical Science, University of Adelaide, Adelaide, SA 5005, Australia
| | | | | | | | | |
Collapse
|
15
|
CHEN HY, ZHANG HY, HUANG YQ, CUI BA, WANG ZY, WANG YB, LIU JP, CHAO AJ. Porcine Interleukin-2 Expression in Insect Cells and Its Enhancement of Pig Immunity to Swine Influenza Virus Inactivated Vaccine. ACTA ACUST UNITED AC 2010. [DOI: 10.1016/s1671-2927(09)60209-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
16
|
Chen HY, Zhao L, Wei ZY, Cui BA, Wang ZY, Li XS, Xia PA, Liu JP. Enhancement of the immunogenicity of an infectious laryngotracheitis virus DNA vaccine by a bicistronic plasmid encoding glycoprotein B and interleukin-18. Antiviral Res 2010; 87:235-41. [PMID: 20553764 DOI: 10.1016/j.antiviral.2010.05.009] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2010] [Revised: 05/18/2010] [Accepted: 05/19/2010] [Indexed: 01/03/2023]
Abstract
A DNA vaccine against infectious laryngotracheitis virus (ILTV) can induce specific humoral and cell-mediated immunity. However, compared to conventional vaccines, DNA vaccines usually induce poor antibody responses. To determine if co-expression of a cytokine can result in a more potent ILTV DNA vaccine, immunogenicity and protective efficacy of a monocistronic vector encoding the glycoprotein B (gB) of ILTV was compared to that of a bicistronic vector separately encoding the gB and chicken interleukin-18. Humoral and cellular responses induced by the DNA vaccines administered to the quadriceps muscle of chickens were evaluated. There were significant differences in antibody levels elicited by either monocistronic or bicistronic DNA vaccines as determined by ELISA. The percentages of CD3(+), CD3(+)CD8(+) and CD3(+)CD4(+) subgroups of peripheral blood T-lymphocytes in chickens immunized with the bicistronic DNA vaccine were higher than those in chickens immunized with monocistronic DNA vaccine. When chickens were challenged with a virulent CG strain of ILTV, the protective efficacy was enhanced significantly after immunization with the bicistronic DNA vaccine. These results demonstrated that co-expression of an adjuvant cytokine from a bicistronic DNA vaccine may be an effective approach to increasing ILTV DNA vaccine immunogenicity.
Collapse
Affiliation(s)
- Hong-Ying Chen
- College of Animal Science and Veterinary Medicine, Henan Agricultural University, Wenhua Road 95#, 450002 Zhengzhou, Henan Province, People's Republic of China.
| | | | | | | | | | | | | | | |
Collapse
|